Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 8Unknown 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 3Immunoblastic Lymphadenopathy 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Hodgkin Disease 2Sezary Syndrome 1Recurrence 1Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Bronchiolitis Obliterans Syndrome 1Anemia, Aplastic 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Cyclophosphamide 9Prednisone 8Etoposide 6Vincristine 5Gemcitabine 5Lenalidomide 4Doxorubicin 4Dexamethasone 3Azacitidine 3liposomal doxorubicin 2endostar protein 2apatinib 2VAP-cyclo protocol 2Ifosfamide 2Cisplatin 2sintilimab 1romidepsin 1ivarmacitinib 1fludarabine phosphate 1fludarabine 1camrelizumab 1Vinorelbine 1Valproic Acid 1Transplantation, Autologous 1TQ-B3525 1Rituximab 1Prednisolone 1Polymerase Chain Reaction 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell, Peripheral × Alemtuzumab × Clear all
NCT00562068 2013-08-26

Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Unknown
30 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡